Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs
Information source: Rambam Health Care Campus
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: NIDDM
Intervention: candesartan (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: Rambam Health Care Campus Official(s) and/or principal investigator(s):
Shlomo Keidar, MD, Principal Investigator, Affiliation: Rambam Health Care Campus
Overall contact:
Shlomo Keidar, MD, Phone: 97248542518, Email: skeidar@rambam.health.gov.il
Summary
This feasibility study is designed to examine modulation of the relative activities of ACE
and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R)
antagonist, Candesartan.
This study will provide a closer insight to the possible involvement of the renin-angiotensin
system (RAS)-related enzymatic components in development or attenuation of vascular
pathogenesis.
Clinical Details
Official title: ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs
Study design: Educational/Counseling/Training, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Pharmacodynamics Study
Primary outcome: ACE and ACE2 activities in monocytes
Eligibility
Minimum age: 18 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Signed informed consent
- Non-smokers
- Type II DM diagnosed patients
- Blood pressure < 135/90
- Serum HbA1C > 7%
- Serum creatinine < 1mg%
- Urine microalbumin < 300 mg/day
- Body mass index (BMI) < 35 kg/m2
Exclusion Criteria:
- Insulin-dependent diabetic patients
- Patient with persistent microalbuminuria
- Patient with history of severe hypertension
- Congestive heart failure
- Patient receiving renin-angiotensin-aldosterone system (RAAS)-related
anti-hypertensive medications.
- Patient with major hepatic disease
Locations and Contacts
Shlomo Keidar, MD, Phone: 97248542518, Email: skeidar@rambam.health.gov.il
Internal Ward "A", Rambam Medical Center, Haifa, Israel
Additional Information
Last updated: February 22, 2006
|
